JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:JAZZ • IE00B4Q5ZN47

163.15 USD
-2.57 (-1.55%)
At close: Feb 5, 2026
163.15 USD
0 (0%)
After Hours: 2/5/2026, 5:37:19 PM
Fundamental Rating

4

Taking everything into account, JAZZ scores 4 out of 10 in our fundamental rating. JAZZ was compared to 191 industry peers in the Pharmaceuticals industry. While JAZZ is still in line with the averages on profitability rating, there are concerns on its financial health. JAZZ scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • JAZZ had positive earnings in the past year.
  • In the past year JAZZ had a positive cash flow from operations.
  • In multiple years JAZZ reported negative net income over the last 5 years.
  • JAZZ had a positive operating cash flow in each of the past 5 years.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • With a decent Return On Assets value of -3.24%, JAZZ is doing good in the industry, outperforming 74.35% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -9.31%, JAZZ is in the better half of the industry, outperforming 75.39% of the companies in the same industry.
  • The Return On Invested Capital of JAZZ (3.95%) is better than 82.20% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for JAZZ is significantly below the industry average of 12.87%.
  • The last Return On Invested Capital (3.95%) for JAZZ is above the 3 year average (3.85%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROIC 3.95%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

  • In the last couple of years the Profit Margin of JAZZ has declined.
  • With an excellent Operating Margin value of 10.92%, JAZZ belongs to the best of the industry, outperforming 83.25% of the companies in the same industry.
  • JAZZ's Operating Margin has declined in the last couple of years.
  • JAZZ's Gross Margin of 88.49% is amongst the best of the industry. JAZZ outperforms 90.05% of its industry peers.
  • JAZZ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 88.49%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, JAZZ has less shares outstanding
  • Compared to 5 years ago, JAZZ has more shares outstanding
  • JAZZ has a worse debt/assets ratio than last year.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 1.53, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
  • JAZZ's Altman-Z score of 1.53 is in line compared to the rest of the industry. JAZZ outperforms 56.54% of its industry peers.
  • JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
  • JAZZ has a better Debt to FCF ratio (4.33) than 84.29% of its industry peers.
  • JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
  • JAZZ has a worse Debt to Equity ratio (1.09) than 73.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Altman-Z 1.53
ROIC/WACC0.53
WACC7.49%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 1.65 indicates that JAZZ should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.65, JAZZ is not doing good in the industry: 68.06% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
  • JAZZ has a worse Quick ratio (1.44) than 63.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.44
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for JAZZ have decreased strongly by -58.39% in the last year.
  • Measured over the past 5 years, JAZZ shows a small growth in Earnings Per Share. The EPS has been growing by 5.47% on average per year.
  • Looking at the last year, JAZZ shows a small growth in Revenue. The Revenue has grown by 4.14% in the last year.
  • Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.67% on average over the next years.
  • The Revenue is expected to grow by 7.06% on average over the next years.
EPS Next Y-61.2%
EPS Next 2Y4.09%
EPS Next 3Y6.32%
EPS Next 5Y7.67%
Revenue Next Year4.66%
Revenue Next 2Y5.44%
Revenue Next 3Y6.29%
Revenue Next 5Y7.06%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • JAZZ is valuated rather expensively with a Price/Earnings ratio of 19.99.
  • Based on the Price/Earnings ratio, JAZZ is valued cheaper than 81.15% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of JAZZ to the average of the S&P500 Index (27.67), we can say JAZZ is valued slightly cheaper.
  • JAZZ is valuated cheaply with a Price/Forward Earnings ratio of 7.11.
  • 92.67% of the companies in the same industry are more expensive than JAZZ, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of JAZZ to the average of the S&P500 Index (27.20), we can say JAZZ is valued rather cheaply.
Industry RankSector Rank
PE 19.99
Fwd PE 7.11
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • JAZZ's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. JAZZ is cheaper than 86.91% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 94.24% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8
EV/EBITDA 11.12
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

  • The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.66
EPS Next 2Y4.09%
EPS Next 3Y6.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (2/5/2026, 5:37:19 PM)

After market: 163.15 0 (0%)

163.15

-2.57 (-1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)02-23
Inst Owners104.02%
Inst Owner Change-1.38%
Ins Owners2.48%
Ins Owner Change1.2%
Market Cap9.91B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts85.22
Price Target220.93 (35.42%)
Short Float %9.08%
Short Ratio4.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.52%
PT rev (3m)15.86%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)10.83%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)51.56%
Revenue NQ rev (1m)0.34%
Revenue NQ rev (3m)-0.67%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.28%
Valuation
Industry RankSector Rank
PE 19.99
Fwd PE 7.11
P/S 2.38
P/FCF 8
P/OCF 7.12
P/B 2.5
P/tB N/A
EV/EBITDA 11.12
EPS(TTM)8.16
EY5%
EPS(NY)22.96
Fwd EY14.07%
FCF(TTM)20.39
FCFY12.5%
OCF(TTM)22.9
OCFY14.04%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)3.66
Graham Number109.37
Profitability
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROCE 5%
ROIC 3.95%
ROICexc 5.1%
ROICexgc 55.75%
OM 10.92%
PM (TTM) N/A
GM 88.49%
FCFM 29.8%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Debt/EBITDA 3.8
Cap/Depr 22.29%
Cap/Sales 3.68%
Interest Coverage 250
Cash Conversion 122.16%
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.44
Altman-Z 1.53
F-Score5
WACC7.49%
ROIC/WACC0.53
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-61.2%
EPS Next 2Y4.09%
EPS Next 3Y6.32%
EPS Next 5Y7.67%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.66%
Revenue Next 2Y5.44%
Revenue Next 3Y6.29%
Revenue Next 5Y7.06%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-57.7%
EBIT Next 3Y5.83%
EBIT Next 5Y7.65%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%

JAZZ PHARMACEUTICALS PLC / JAZZ FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.


Can you provide the financial health for JAZZ stock?

The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -61.2% in the next year.